Calmactin is the prescription drug formulated using the key ingredient called Cilansetron by Solvay Pharmaceuticals. The drug is presently under testing in the clinical trials and the headline results from the first two large placebo-controlled phase III efficacy studies exhibit the credible indication for the patient benefits of Calmactin for the treatment of irritable bowel syndrome that are diarrhea predominant.

The formulators Solvay Pharmaceuticals is now running the full phase III clinical program with Calmactin, the effective and discerning 5HT3 antagonist that affects the serotonin actions in the gut; the serotonin is involved in the directive of visceral pain via 5-HT3 receptors situated in the lower gastrointestinal tract. The phase III clinical study was conducted on over 4,000 patients.

Calmactin has exhibited the benefits in both males and females during the phase II placebo controlled clinical studies as well as two phase III placebo controlled clinical studies, conducted in the United States, Europe and other countries. Calmactin is being developed to minimize abdominal pain, reduce stool frequency and improve firmness of stool in the IBS patients who are diarrhea predominant. Calmactin was found to be more effective as compared to placebo in both men and women in providing sufficient symptom relief. The effectiveness however, varied by dosages.

The most often side effects that were noticed included constipation and flatulence i.e. intestinal wind. No constipation cases were ever reported to be serious as well as none of the case of ischemic colitis – inflammation of colon lining were reported during the specific clinical study.